Author:
Mesa Ruben,Gale Robert Peter
Subject
Cancer Research,Oncology,Hematology
Reference6 articles.
1. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera;James;Nature,2005
2. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials;Pardanani;Leukemia,2008
3. A phase I study of TG101348, an orally bioavailable JAK2-selective inhibitor, in patients with myelofibrosis;Pardanani;Blood,2008
4. The JAK inhibitor, INCB018424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMYELOFIBROSIS) and post-polycythemia/essential thrombocythemia myelofibrosis (post PV/ETMYELOFIBROSIS);Verstovsek,2008
5. A phase 2A study of the histone-deacetylase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms;Rambaldi;Blood,2008
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献